Trials / Not Yet Recruiting
Not Yet RecruitingNCT07206290
Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease
Albuminuria Reduction Trial and Investigation With Survodutide Treatment in CKD
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- University Medical Center Groningen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The ARTIST-CKD trial is a clinical study evaluating the effect of weekly subcutaneous administration of survodutide (3.6 mg) on kidney function in patients with chronic kidney disease (CKD) and elevated albuminuria. The primary objective is to determine whether survodutide leads to early, sustained, and clinically meaningful reductions in albuminuria, regardless of diabetes status.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Survodutide (BI 456906) | 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 3.6 mg s.c. weekly |
| DRUG | Placebo | Placebo matching survodutide |
Timeline
- Start date
- 2026-03-02
- Primary completion
- 2027-11-30
- Completion
- 2027-11-30
- First posted
- 2025-10-03
- Last updated
- 2025-10-03
Source: ClinicalTrials.gov record NCT07206290. Inclusion in this directory is not an endorsement.